Synapse - Larry Norton

Results (183)

Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible

Journal Article

Dang, C.; D'Andrea, G.; Lake, D.; Sugarman, S.; Fornier, M.; Moynahan, M. E.; Gilewski, T.; Hurria, A.; Mills, N.; Troso-Sandoval, T.; more...
Clinical Breast Cancer (2008)

Fulltext@MSK | Save

Phase I study of a novel capecitabine schedule based on Norton-Simon mathematical modeling

Meeting Abstract

Theodoulou, M.; Traina, T. A.; Dugan, U.; Lake, D.; Fornier, M.; Feigin, K.; Patil, S.; Edwards, C.; Norton, L.; Hudis, C. A.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

Adjuvant (adj) bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-p) in early stage breast cancer (BC) patients (pts): Cardiac safety

Meeting Abstract

Dickler, M. N.; Traina, T.; Panageas, K.; Steingart, R.; Dang, C.; Fornier, M.; Sugarman, S.; Norton, L.; Hudis, C.; Rugo, H.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

Cardiac safety of adjuvant bevacizumab plus dose-dense doxorubicin/cyclophosphamide followed by nanoparticle albumin-bound paclitaxel in patients with early stage breast cancer

Meeting Abstract

Mcarthur, H. L.; Rugo, H.; Paulson, M.; Rourke, M.; Traina, T.; Panageas, K.; Steingart, R.; Dang, C.; Fornier, M.; Park, J.; more...
Breast Cancer Research and Treatment (2007)

Fulltext@MSK | Save

Clinical, morphologic and immunophenotypic characteristics of primary breast carcinomas (BC) with brain metastases (BM)

Meeting Abstract

Brogi, E.; Murray, M. P.; Patil, S.; Akram, M.; Nehhozina, T.; Norton, L.; Seidman, A.; Tan, L. K.
Modern Pathology (2007)

Fulltext@MSK | Save

Clinical, morphologic and immunophenotypic characteristics of primary breast carcinomas (BC) with brain metastases (BM)

Meeting Abstract

Brogi, E.; Murray, M. P.; Patil, S.; Akram, M.; Nehhozina, T.; Norton, L.; Seidman, A.; Tan, L. K.
Laboratory Investigation (2007)

Fulltext@MSK | Save

Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21

Journal Article

Gilewski, T. A.; Ragupathi, G.; Dickler, M.; Powell, S.; Bhuta, S.; Panageas, K.; Koganty, R. R.; Chin-Eng, J.; Hudis, C.; Norton, L.; more...
Clinical Cancer Research (2007)

Fulltext@MSK | Save

Increased dose density is feasible: A pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer

Journal Article

Fornier, M. N.; Seidman, A. D.; Lake, D.; D'Andrea, G.; Bromberg, J.; Robson, M.; Van Poznak, C.; Panageas, K. S.; Atienza, M.; Norton, L.; more...
Clinical Cancer Research (2007)

Fulltext@MSK | Save

Optimizing chemotherapy administration: A phase I study of biweekly capecitabine dose and schedule based on Norton-Simon mathematical modeling

Meeting Abstract

Traina, T. A.; Theodoulou, M.; Dugan, U.; Feigin, K.; Panageas, K.; Hodgman, E.; Norton, L.; Hudis, C. A.
Breast Cancer Research and Treatment (2006)

Fulltext@MSK | Save

Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC)

Meeting Abstract

Traina, T. A.; Rugo, H.; Caravelli, J.; Yeh, B.; Panageas, K.; Bruckner, J.; Norton, L.; Park, J.; Hudis, C.; Dickler, M.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save